Homa Timlin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Homa Timlin has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
Duvuru Geetha
Johns Hopkins University School of Medicine
5 shared publications- Rebecca L. Manno
Johns Hopkins University
5 shared publications - Uzma Haque
Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, USA
4 shared publications - Duvuru Geetha
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
3 shared publications - Eric Dein
Rheumatology, Johns Hopkins Bayview Medical Center, Baltimore, USA
3 shared publications - Kirthi Machireddy
Other, University of the Sciences In Philadelphia
3 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by Springer Nature in Cureus
- Vol. 18 (4) , e107549
The Inverted Pyramid Approach: Early Combination Therapy With Voclosporin and Obinutuzumab in Active Lupus Nephritis
Achieving remission or low disease activity in systemic lupus erythematosus reduces long-term organ damage, disease flares, and corticosteroid exposure. Kidney involvement from lupus nephritis is often progressive and associated with adverse long-term outcomes. Early, effective immunosuppression during the active inflammatory phase of lupus nephritis is linked to improved renal outcomes. Although voclosporin and obinutuzumab have each demonstrated efficacy in lupus nephritis, real-world data on their combined use remain limited. Here, we report outcomes in three patients with active lupus nephritis who were treated with both Food and Drug Administration (FDA)-approved agents.
- 22 April 2026
- Published by Springer Nature in Cureus
- Vol. 18 (4) , e107549
Open AccessThe Inverted Pyramid Approach: Early Combination Therapy With Voclosporin and Obinutuzumab in Active Lupus Nephritis
Achieving remission or low disease activity in systemic lupus erythematosus reduces long-term organ damage, disease flares, and corticosteroid exposure. Kidney involvement from lupus nephritis is often progressive and associated with adverse long-term outcomes. Early, effective immunosuppression during the active inflammatory phase of lupus nephritis is linked to improved renal outcomes. Although voclosporin and obinutuzumab have each demonstrated efficacy in lupus nephritis, real-world data on their combined use remain limited. Here, we report outcomes in three patients with active lupus nephritis who were treated with both Food and Drug Administration (FDA)-approved agents.
- 16 April 2026
- Published by SAGE Publications in Lupus
- Vol. 35 (8) , 810-817
Association between interstitial fibrosis/tubular atrophy (IFTA) on kidney biopsies and anti Ro60 antibody positivity in patients with lupus nephritis (LN)
Background: Interstitial fibrosis and tubular atrophy (IFTA) are key predictors of renal outcomes in lupus nephritis (LN), but serologic markers that identify patients at higher risk for tubulointerstitial damage are poorly defined. Anti-Ro60 antibodies are associated with heightened systemic immune activation and worse renal outcomes in systemic lupus erythematosus, but their relationship to IFTA in LN is unknown. Methods: We performed a retrospective cohort study of adults with biopsy-confirmed LN at a single academic center. Clinical data, autoantibody profiles, and renal histopathology were abstracted from the medical record at or near the time of kidney biopsy. Ro60 status was determined by standard clinical immunoassays. IFTA severity was graded by a renal pathologist as none, mild, moderate, or severe. Ordinal logistic regression was used to evaluate the association between Ro60 positivity and IFTA severity. A multivariable proportional odds model included Ro60 positivity (primary exposure), Black race (the only variable with p < 0.05 in the univariable analysis), and ISN/RPS class IV LN (an a priori clinical risk factor for fibrosis). Sensitivity analyses included dichotomizing IFTA (absent/mild vs moderate/severe), excluding the single severe IFTA case, and restricting to Black patients. Results: Forty-one patients met the inclusion criteria; 16 (39%) were Ro60-positive, and 25 (61%) were Ro60-negative. Ro60-positive patients were more often Black and had lower C3 and C4 levels; the distribution of LN classes was similar between groups. In univariable analysis, Ro60 positivity was associated with higher odds of more severe IFTA (OR 3.05; 95% CI 0.86–11.5; p = 0.087), while Black race was strongly associated with worse IFTA (OR 7.82; 95% CI 1.02–93.12; p = 0.014). In the multivariable model limited to 29 complete cases, Ro60 positivity remained associated with higher IFTA severity (OR 2.76; 95% CI 0.77–13.04; p = 0.127), and Black race remained the strongest predictor (OR 8.06; 95% CI 0.92–275.61; p = 0.015); class IV LN was not significantly associated with IFTA (OR 1.90; 95% CI 0.37–13.24; p = 0.371). In a sensitivity analysis excluding the single patient with severe IFTA, the association between Ro60 positivity and IFTA strengthened (OR 5.25; p = 0.028), and Black race remained strongly associated with worse IFTA (OR 15.79; p = 0.005). Conclusions: In this biopsy-based LN cohort, Ro60 positivity was associated with a consistent trend toward more severe IFTA, with a statistically significant association in sensitivity analysis excluding one severe outlier case. Black race was the most robust predictor of IFTA severity, highlighting persistent racial disparities in LN-related kidney damage. These findings support the hypothesis that anti-Ro60 antibodies contribute to tubulointerstitial injury and suggest that Ro60 status may help identify LN patients at higher risk for chronic structural damage. Larger, prospective studies are needed to confirm these associations and clarify the prognostic role of Ro60 in LN.
- 16 April 2026
- Published by SAGE Publications in Lupus
- Vol. 35 (8) , 810-817
Association between interstitial fibrosis/tubular atrophy (IFTA) on kidney biopsies and anti Ro60 antibody positivity in patients with lupus nephritis (LN)
Background: Interstitial fibrosis and tubular atrophy (IFTA) are key predictors of renal outcomes in lupus nephritis (LN), but serologic markers that identify patients at higher risk for tubulointerstitial damage are poorly defined. Anti-Ro60 antibodies are associated with heightened systemic immune activation and worse renal outcomes in systemic lupus erythematosus, but their relationship to IFTA in LN is unknown. Methods: We performed a retrospective cohort study of adults with biopsy-confirmed LN at a single academic center. Clinical data, autoantibody profiles, and renal histopathology were abstracted from the medical record at or near the time of kidney biopsy. Ro60 status was determined by standard clinical immunoassays. IFTA severity was graded by a renal pathologist as none, mild, moderate, or severe. Ordinal logistic regression was used to evaluate the association between Ro60 positivity and IFTA severity. A multivariable proportional odds model included Ro60 positivity (primary exposure), Black race (the only variable with p < 0.05 in the univariable analysis), and ISN/RPS class IV LN (an a priori clinical risk factor for fibrosis). Sensitivity analyses included dichotomizing IFTA (absent/mild vs moderate/severe), excluding the single severe IFTA case, and restricting to Black patients. Results: Forty-one patients met the inclusion criteria; 16 (39%) were Ro60-positive, and 25 (61%) were Ro60-negative. Ro60-positive patients were more often Black and had lower C3 and C4 levels; the distribution of LN classes was similar between groups. In univariable analysis, Ro60 positivity was associated with higher odds of more severe IFTA (OR 3.05; 95% CI 0.86–11.5; p = 0.087), while Black race was strongly associated with worse IFTA (OR 7.82; 95% CI 1.02–93.12; p = 0.014). In the multivariable model limited to 29 complete cases, Ro60 positivity remained associated with higher IFTA severity (OR 2.76; 95% CI 0.77–13.04; p = 0.127), and Black race remained the strongest predictor (OR 8.06; 95% CI 0.92–275.61; p = 0.015); class IV LN was not significantly associated with IFTA (OR 1.90; 95% CI 0.37–13.24; p = 0.371). In a sensitivity analysis excluding the single patient with severe IFTA, the association between Ro60 positivity and IFTA strengthened (OR 5.25; p = 0.028), and Black race remained strongly associated with worse IFTA (OR 15.79; p = 0.005). Conclusions: In this biopsy-based LN cohort, Ro60 positivity was associated with a consistent trend toward more severe IFTA, with a statistically significant association in sensitivity analysis excluding one severe outlier case. Black race was the most robust predictor of IFTA severity, highlighting persistent racial disparities in LN-related kidney damage. These findings support the hypothesis that anti-Ro60 antibodies contribute to tubulointerstitial injury and suggest that Ro60 status may help identify LN patients at higher risk for chronic structural damage. Larger, prospective studies are needed to confirm these associations and clarify the prognostic role of Ro60 in LN.
- Open Access
- 20 March 2026
- Published by Springer Nature in Cureus
- Vol. 18 (3)
Rapid Reduction in Proteinuria With the Initiation of Voclosporin in Lupus Nephritis: A Single-Center Experience
Background and purpose Lupus nephritis (LN) is a severe, life-threatening complication of systemic lupus erythematosus (SLE). Reduction in proteinuria is strongly associated with long‑term renal outcomes and is a key endpoint in LN clinical trials. Early initiation of immunosuppressive therapy improves renal recovery, and a rapid decline in proteinuria correlates with achieving remission at 12 months. Voclosporin may cause a mild, early decline in estimated glomerular filtration rate (eGFR) due to hemodynamic effects, which typically stabilizes with continued therapy. This study evaluated the effect of voclosporin on early (≤12‑week) proteinuria reduction and its tolerability when used in combination with standard immunosuppressive therapy in patients with biopsy‑proven LN. Methods We conducted a retrospective cohort study using the institutional review board-approved Epic Lupus Database at Johns Hopkins Bayview Medical Center, Baltimore, MD, USA. Patients were included if they had biopsy‑confirmed LN and received voclosporin. Demographics, clinical characteristics, and immunosuppressive regimens were abstracted from electronic medical records. Relative changes in urine protein creatinine ratio (UPCR) from baseline to four, eight, and 12 weeks were calculated with corresponding 95% confidence intervals (CIs). Results Twenty‑five patients with biopsy‑proven LN were treated with voclosporin; all received concurrent hydroxychloroquine and tolerated voclosporin without discontinuation. Most patients were treated with mycophenolate or mycophenolic acid (92%) and corticosteroids (96%; median prednisone‑equivalent dose 15 mg/day). Relative reductions in UPCR from baseline were observed at four weeks (-0.27; 95% CI, -0.49 to -0.05), eight weeks (-0.51; 95% CI, -0.65 to -0.37), and 12 weeks (-0.57; 95% CI, -0.71 to -0.43). No statistically significant change in eGFR was observed over the 12‑week treatment period. Conclusion Initiation of voclosporin in combination with standard immunosuppressive therapy in biopsy‑proven LN was associated with early improvement in renal activity, as reflected by significant reductions in UPCR beginning at four weeks. To our knowledge, this represents the largest case series to date describing early real‑world outcomes with voclosporin in LN. Given that persistent proteinuria may indicate ongoing renal inflammation and/or chronic damage, these findings support consideration of voclosporin as a first‑line therapeutic option for active LN.
- 20 March 2026
- Published by Springer Nature in Cureus
- Vol. 18 (3)
Open AccessRapid Reduction in Proteinuria With the Initiation of Voclosporin in Lupus Nephritis: A Single-Center Experience
Background and purpose Lupus nephritis (LN) is a severe, life-threatening complication of systemic lupus erythematosus (SLE). Reduction in proteinuria is strongly associated with long‑term renal outcomes and is a key endpoint in LN clinical trials. Early initiation of immunosuppressive therapy improves renal recovery, and a rapid decline in proteinuria correlates with achieving remission at 12 months. Voclosporin may cause a mild, early decline in estimated glomerular filtration rate (eGFR) due to hemodynamic effects, which typically stabilizes with continued therapy. This study evaluated the effect of voclosporin on early (≤12‑week) proteinuria reduction and its tolerability when used in combination with standard immunosuppressive therapy in patients with biopsy‑proven LN. Methods We conducted a retrospective cohort study using the institutional review board-approved Epic Lupus Database at Johns Hopkins Bayview Medical Center, Baltimore, MD, USA. Patients were included if they had biopsy‑confirmed LN and received voclosporin. Demographics, clinical characteristics, and immunosuppressive regimens were abstracted from electronic medical records. Relative changes in urine protein creatinine ratio (UPCR) from baseline to four, eight, and 12 weeks were calculated with corresponding 95% confidence intervals (CIs). Results Twenty‑five patients with biopsy‑proven LN were treated with voclosporin; all received concurrent hydroxychloroquine and tolerated voclosporin without discontinuation. Most patients were treated with mycophenolate or mycophenolic acid (92%) and corticosteroids (96%; median prednisone‑equivalent dose 15 mg/day). Relative reductions in UPCR from baseline were observed at four weeks (-0.27; 95% CI, -0.49 to -0.05), eight weeks (-0.51; 95% CI, -0.65 to -0.37), and 12 weeks (-0.57; 95% CI, -0.71 to -0.43). No statistically significant change in eGFR was observed over the 12‑week treatment period. Conclusion Initiation of voclosporin in combination with standard immunosuppressive therapy in biopsy‑proven LN was associated with early improvement in renal activity, as reflected by significant reductions in UPCR beginning at four weeks. To our knowledge, this represents the largest case series to date describing early real‑world outcomes with voclosporin in LN. Given that persistent proteinuria may indicate ongoing renal inflammation and/or chronic damage, these findings support consideration of voclosporin as a first‑line therapeutic option for active LN.
- Open Access
- 1 January 2026
- Published by S. Karger AG in Glomerular Diseases
- Vol. 6 (1) , 208-215
Case Series of the Combination of Voclosporin and Belimumab Treatment of Lupus Nephritis
Introduction: Lupus nephritis (LN) remains challenging with high treatment failure and relapse rates. Current therapies often fail to achieve sustained renal remission. The objective of this research was to assess the safety and clinical effectiveness of dual therapy using voclosporin and belimumab in individuals with LN confirmed via kidney biopsy. Methods: Retrospective case series of 16 female patients (median age 36) with kidney biopsy-proven LN treated with voclosporin (15.8–23.7 mg BID) plus belimumab (200 mg SC weekly/IV) between 2012 and 2025 in routine clinical practice. Baseline was defined as the laboratory value closest to the first kidney biopsy. Longitudinal data for urine protein-to-creatinine ratio (UPCR), serum creatinine, C3/C4 complement, and anti-dsDNA antibodies were analyzed using the Wilcoxon signed-rank test. Results: Initiation of voclosporin and belimumab was associated with a marked reduction in proteinuria, with median UPCR declining from 2.175 g/g to 0.082 g/g and remaining low at final follow-up (0.131 g/g; all p ≤ 0.0005). Serologic markers improved concurrently, with increases in complement levels (C3 65.0–109.5, C4 6.5–20.5) and a decline in median anti-dsDNA (51.5–12.0). 62.5% of patients tapered corticosteroids to ≤5 mg/day or discontinued them, while serum creatinine increased modestly from 0.77 to 0.89 mg/dL. Conclusions: The combination of voclosporin and belimumab is highly effective in inducing rapid and sustained renal remission and facilitating a significant reduction in corticosteroid dose in patients with LN.
- 1 January 2026
- Published by S. Karger AG in Glomerular Diseases
- Vol. 6 (1) , 208-215
Open AccessCase Series of the Combination of Voclosporin and Belimumab Treatment of Lupus Nephritis
Introduction: Lupus nephritis (LN) remains challenging with high treatment failure and relapse rates. Current therapies often fail to achieve sustained renal remission. The objective of this research was to assess the safety and clinical effectiveness of dual therapy using voclosporin and belimumab in individuals with LN confirmed via kidney biopsy. Methods: Retrospective case series of 16 female patients (median age 36) with kidney biopsy-proven LN treated with voclosporin (15.8–23.7 mg BID) plus belimumab (200 mg SC weekly/IV) between 2012 and 2025 in routine clinical practice. Baseline was defined as the laboratory value closest to the first kidney biopsy. Longitudinal data for urine protein-to-creatinine ratio (UPCR), serum creatinine, C3/C4 complement, and anti-dsDNA antibodies were analyzed using the Wilcoxon signed-rank test. Results: Initiation of voclosporin and belimumab was associated with a marked reduction in proteinuria, with median UPCR declining from 2.175 g/g to 0.082 g/g and remaining low at final follow-up (0.131 g/g; all p ≤ 0.0005). Serologic markers improved concurrently, with increases in complement levels (C3 65.0–109.5, C4 6.5–20.5) and a decline in median anti-dsDNA (51.5–12.0). 62.5% of patients tapered corticosteroids to ≤5 mg/day or discontinued them, while serum creatinine increased modestly from 0.77 to 0.89 mg/dL. Conclusions: The combination of voclosporin and belimumab is highly effective in inducing rapid and sustained renal remission and facilitating a significant reduction in corticosteroid dose in patients with LN.
- 29 April 2022
- Published by SAGE Publications in Lupus
- Vol. 31 (8) , 1007-1011
New-onset lupus nephritis associated with COVID-19 infection
A dysregulated immune response plays a critical role in systemic lupus erythematosus (SLE) pathogenesis. Environmental factors such as viruses, including coronavirus 2 (COVID-19), have been described to play a role in SLE presentation and exacerbation. These viruses trigger a host’s humoral and cellular immunities typically essential in elimination of the viral infection. We present a case of a Hispanic male who developed new-onset lupus nephritis class II after a COVID-19 infection.
- 29 April 2022
- Published by SAGE Publications in Lupus
- Vol. 31 (8) , 1007-1011
New-onset lupus nephritis associated with COVID-19 infection
A dysregulated immune response plays a critical role in systemic lupus erythematosus (SLE) pathogenesis. Environmental factors such as viruses, including coronavirus 2 (COVID-19), have been described to play a role in SLE presentation and exacerbation. These viruses trigger a host’s humoral and cellular immunities typically essential in elimination of the viral infection. We present a case of a Hispanic male who developed new-onset lupus nephritis class II after a COVID-19 infection.
- Open Access
- 26 April 2022
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 9 (2) , 108-110
Adalimumab-Induced Lupus Nephritis: Case Report and Review of the Literature
Tumor necrosis factor-alpha inhibitors are known causative agents of systemic lupus erythemato- sus but have rarely been implicated in lupus nephritis. A patient with Crohn’s disease on long-term adalimumab treatment presented with new-onset Raynaud’s phenomenon and was found to have hematuria and proteinuria. Elevated antinuclear, anti-dsDNA, and MPO antibodies were found. A renal biopsy confirmed the diagnosis of lupus nephritis. Adalimumab was discontinued ensuing improvement in urine studies and resolution of dsDNA and MPO antibodies. Adalimumab can induce systemic lupus erythematosus and lupus nephritis. Cite this article as: Kazzi B, Gudenkauf B, Fine D, et al. Adalimumab-induced lupus nephritis: Case report and review of the literature. Eur J Rheumatol. 2022;9(2): 108-110.
- 26 April 2022
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 9 (2) , 108-110
Open AccessAdalimumab-Induced Lupus Nephritis: Case Report and Review of the Literature
Tumor necrosis factor-alpha inhibitors are known causative agents of systemic lupus erythemato- sus but have rarely been implicated in lupus nephritis. A patient with Crohn’s disease on long-term adalimumab treatment presented with new-onset Raynaud’s phenomenon and was found to have hematuria and proteinuria. Elevated antinuclear, anti-dsDNA, and MPO antibodies were found. A renal biopsy confirmed the diagnosis of lupus nephritis. Adalimumab was discontinued ensuing improvement in urine studies and resolution of dsDNA and MPO antibodies. Adalimumab can induce systemic lupus erythematosus and lupus nephritis. Cite this article as: Kazzi B, Gudenkauf B, Fine D, et al. Adalimumab-induced lupus nephritis: Case report and review of the literature. Eur J Rheumatol. 2022;9(2): 108-110.
- 23 March 2021
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 28 (1) , e245-e248
Systemic Lupus Erythematosus and Common Variable Immunodeficiency
Systemic lupus erythematosus (SLE) and common variable immunodeficiency (CVID) are both conditions defined by immune system dysfunction: one hyperactive, the other hypoactive. Although uncommon, these diseases can coexist in the same individual. This review aims to assess the state of the literature on the relationship between SLE and CVID, particularly when workup for CVID should be considered in individuals with SLE and how CVID in individuals with SLE should be treated.
- 23 March 2021
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 28 (1) , e245-e248
Systemic Lupus Erythematosus and Common Variable Immunodeficiency
Systemic lupus erythematosus (SLE) and common variable immunodeficiency (CVID) are both conditions defined by immune system dysfunction: one hyperactive, the other hypoactive. Although uncommon, these diseases can coexist in the same individual. This review aims to assess the state of the literature on the relationship between SLE and CVID, particularly when workup for CVID should be considered in individuals with SLE and how CVID in individuals with SLE should be treated.
- 24 December 2020
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 28 (1) , e141-e144
The Effect of Mycophenolate Mofetil as First-Line Therapy on the Timing of Urine Protein–to–Creatinine Ratio Reduction in Immunosuppressant-Naive Patients With Lupus Nephritis at a Single Center
Background/Objectives: Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis (LN). The purpose of this study was to assess the effect of mycophenolate mofetil (MMF) on the timing of urine protein–to–creatinine ratio reaching 200 mg or less after starting MMF as initial therapy for class III, IV, or V in immunosuppressant-naive patients with LN. Methods: Patients who had a diagnosis of biopsy-proven LN were included in this cohort study. The initial dose of MMF was 1000 mg twice daily. If no improvement, it was increased to 1500 mg twice daily after 1 month. For statistical analysis, exact binomial distribution 95% confidence intervals were calculated. Results: Nine patients were identified. There were 3 patients with class III, 3 with class IV, 1 with class III to V, 1 with class II to V, and 1 with class V lupus nephritis. The majority were African Americans (70%). At baseline, proteinuria ranged between 0.41 and 4 g, and 88% had normal estimated glomerular filtration rate. Forty-four percent of patients reached 0.28 g of proteinuria within 8 weeks of starting MMF (95% confidence interval, 14%–79%), all of which maintained the same level of response and normal estimated glomerular filtration rate at 12 months. Thirty-three percent of patients achieved the American College of Rheumatology complete response at 8 weeks. Conclusions: This study demonstrates that only a minority of immunosuppressant-naive LN patients achieved the American College of Rheumatology complete response at 8 weeks after initiation of MMF. A rapid decline in the proteinuria to 0.28 g within the first 8 weeks of the treatment correlated strongly with achieving the same level of response at 12 months.
- 24 December 2020
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 28 (1) , e141-e144
The Effect of Mycophenolate Mofetil as First-Line Therapy on the Timing of Urine Protein–to–Creatinine Ratio Reduction in Immunosuppressant-Naive Patients With Lupus Nephritis at a Single Center
Background/Objectives: Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis (LN). The purpose of this study was to assess the effect of mycophenolate mofetil (MMF) on the timing of urine protein–to–creatinine ratio reaching 200 mg or less after starting MMF as initial therapy for class III, IV, or V in immunosuppressant-naive patients with LN. Methods: Patients who had a diagnosis of biopsy-proven LN were included in this cohort study. The initial dose of MMF was 1000 mg twice daily. If no improvement, it was increased to 1500 mg twice daily after 1 month. For statistical analysis, exact binomial distribution 95% confidence intervals were calculated. Results: Nine patients were identified. There were 3 patients with class III, 3 with class IV, 1 with class III to V, 1 with class II to V, and 1 with class V lupus nephritis. The majority were African Americans (70%). At baseline, proteinuria ranged between 0.41 and 4 g, and 88% had normal estimated glomerular filtration rate. Forty-four percent of patients reached 0.28 g of proteinuria within 8 weeks of starting MMF (95% confidence interval, 14%–79%), all of which maintained the same level of response and normal estimated glomerular filtration rate at 12 months. Thirty-three percent of patients achieved the American College of Rheumatology complete response at 8 weeks. Conclusions: This study demonstrates that only a minority of immunosuppressant-naive LN patients achieved the American College of Rheumatology complete response at 8 weeks after initiation of MMF. A rapid decline in the proteinuria to 0.28 g within the first 8 weeks of the treatment correlated strongly with achieving the same level of response at 12 months.
- Open Access
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 5 (1) , 5-8
Outcomes of hydralazine induced renal vasculitis
Objective: Hydralazine has been implicated as an etiologic agent for lupus-like syndrome and vasculitis. Hydralazine-induced vasculitis frequently affects the kidney, but the long-term renal outcomes in these patients have not yet been studied. Methods: Patients who had a diagnosis of ANCA-associated vasculitis (AAV) and were on hydralazine at the time of AAV diagnosis were included in this retrospective cohort study. Clinical and laboratory data were obtained from the review of medical records. Results: Seven patients met the criteria for hydralazine-induced AAV. Five patients (71%) were African-American and four (57%) were female. The median age was 69 years at the time of diagnosis. All patients had renal involvement with two of them showing lung involvement as well. All patients had positive MPO antibody and one patient had positive PR3 antibody. ANA was positive in all patients, and three of seven patients had positive anti-histone antibody. All of them were treated with immunosuppression and withdrawal of hydralazine. Three patients reached end-stage renal disease. The median follow-up time was 13 months. Conclusion: Renal involvement in hydralazine-induced AAV was universal and can be associated with a poor renal outcome despite immunosuppressive therapy. Cite this article as: Timlin H, Liebowitz JE, Jaggi K, Geetha D. Outcomes of hydralazine induced renal vasculitis. Eur J Rheumatol 2018; 5: 5-8.
- 3 September 2019
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 5 (1) , 5-8
Open AccessOutcomes of hydralazine induced renal vasculitis
Objective: Hydralazine has been implicated as an etiologic agent for lupus-like syndrome and vasculitis. Hydralazine-induced vasculitis frequently affects the kidney, but the long-term renal outcomes in these patients have not yet been studied. Methods: Patients who had a diagnosis of ANCA-associated vasculitis (AAV) and were on hydralazine at the time of AAV diagnosis were included in this retrospective cohort study. Clinical and laboratory data were obtained from the review of medical records. Results: Seven patients met the criteria for hydralazine-induced AAV. Five patients (71%) were African-American and four (57%) were female. The median age was 69 years at the time of diagnosis. All patients had renal involvement with two of them showing lung involvement as well. All patients had positive MPO antibody and one patient had positive PR3 antibody. ANA was positive in all patients, and three of seven patients had positive anti-histone antibody. All of them were treated with immunosuppression and withdrawal of hydralazine. Three patients reached end-stage renal disease. The median follow-up time was 13 months. Conclusion: Renal involvement in hydralazine-induced AAV was universal and can be associated with a poor renal outcome despite immunosuppressive therapy. Cite this article as: Timlin H, Liebowitz JE, Jaggi K, Geetha D. Outcomes of hydralazine induced renal vasculitis. Eur J Rheumatol 2018; 5: 5-8.